eligibility_summary
Inclusion: Adults ≥18 with advanced/metastatic solid tumors after standard therapy, measurable lesion, ECOG 0–1 (0–2 expansion), ≥12‑wk survival, adequate organ/marrow, CrCl>30, LVEF≥40, consent/contraception. Exclusion: concurrent trials, recent Tx, active CNS mets, >1 prior PD‑1/PD‑L1 or any anti‑CD47, autoimmune disease or steroids, recent major surgery, serious cardiac/VTE/pulmonary disease, infection/TB or live vaccine ≤4 wks, HIV/HBV/HCV, PD‑1/PD‑L1 allergy, irAE stop, investigator decision.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: IMM2520, an IV recombinant bispecific monoclonal antibody targeting PD‑L1 and CD47. Mechanisms of action: (1) PD‑L1 blockade releases the PD‑1/PD‑L1 immune checkpoint, restoring activation and cytotoxicity of T cells, (2) CD47 blockade disrupts the CD47–SIRPα “don’t‑eat‑me” signal, promoting macrophage-mediated phagocytosis and improved antigen presentation. Drug type: bispecific IgG immunotherapy. Cells/pathways targeted: PD‑L1 on tumor and myeloid cells, PD‑1 pathway on T cells, CD47 on tumor/erythroid cells, SIRPα signaling in macrophages/dendritic cells. Expected immune effects: increased tumor cell phagocytosis and cross-priming, greater effector T‑cell infiltration/function. Phase 1, single-arm dose escalation (0.1–6 mg/kg weekly) with expansion in advanced solid tumors.